AstraZeneca PLC
HealthcareNYSE:AZN · New York Stock Exchange
-$2.51 today
Vol 1.39M · Avg 1.95M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $10.2B +17.7% | $8.7B +26.0% | $6.9B +175.8% | $2.5B +1043.8% | -$265.0M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $5.7B +13.2% | $5.1B +2.7% | $4.9B -10.0% | $5.5B -16.1% | $6.5B | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 +100.0% | -$619.0M -0.7% | -$615.0M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 | $0 -100.0% | $579.0M -6.5% | $619.0M +0.7% | $615.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$1.2B -30.2% | -$893.0M -397.7% | $300.0M -92.0% | $3.8B +85.9% | $2.0B | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 +100.0% | -$1.6B -14.0% | -$1.4B -5.6% | -$1.3B -40.4% | -$961.0M | $592.6M | $1.3B | $626.2M |
| Inventory | $0 +100.0% | -$131.0M +80.4% | -$669.0M -117.0% | $3.9B +149.9% | $1.6B | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $0 | $0 -100.0% | $1.4B +5.6% | $1.3B +40.4% | $961.0M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$1.2B -234.8% | $862.0M -11.0% | $969.0M +626.6% | -$184.0M -141.4% | $444.0M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$220.7M +78.0% | -$1.0B +57.7% | -$2.4B -22.6% | -$1.9B +16.9% | -$2.3B | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $14.6B +22.9% | $11.9B +14.7% | $10.3B +5.5% | $9.8B +64.5% | $6.0B | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$2.8B +38.7% | -$4.6B -21.4% | -$3.8B -46.9% | -$2.6B -16.9% | -$2.2B | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$1.2B +68.7% | -$3.9B -233.1% | -$1.2B -11.1% | -$1.1B +88.8% | -$9.4B | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 +100.0% | -$96.0M +29.4% | -$136.0M +14.5% | -$159.0M +13.6% | -$184.0M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 -100.0% | $108.0M -16.3% | $129.0M +207.1% | $42.0M -60.0% | $105.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$2.8B -29.3% | -$2.1B -41.1% | -$1.5B -292.3% | $789.0M +20.6% | $654.0M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$6.8B +14.7% | -$8.0B -96.4% | -$4.1B -37.3% | -$3.0B +73.2% | -$11.1B | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$1.7B -193.2% | $1.8B +287.5% | -$965.0M +19.4% | -$1.2B -115.2% | $7.9B | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $40.9M +195.1% | -$43.0M -230.3% | $33.0M +13.8% | $29.0M +0.0% | $29.0M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$719.7M | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | -$5.1B -9.8% | -$4.6B -3.3% | -$4.5B -2.7% | -$4.4B -13.2% | -$3.9B | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$133.7M +88.2% | -$1.1B +1.8% | -$1.2B +10.6% | -$1.3B -208.9% | -$418.0M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$7.5B -88.8% | -$4.0B +39.2% | -$6.6B +3.8% | -$6.8B -287.0% | $3.6B | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $46.0M +149.5% | -$93.0M -55.0% | -$60.0M +25.0% | -$80.0M -29.0% | -$62.0M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $269.0M +229.3% | -$208.0M +39.9% | -$346.0M -529.1% | -$55.0M +96.4% | -$1.5B | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $11.8B +61.7% | $7.3B +10.8% | $6.6B -9.3% | $7.2B +92.3% | $3.8B | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Eli Lilly and Company
NYSE:LLY
$1.08T
Johnson & Johnson
NYSE:JNJ
$578.23B
AbbVie Inc.
NYSE:ABBV
$401.62B
Roche Holding AG
RHHBY
$332.93B
Merck & Co., Inc.
NYSE:MRK
$296.47B
Novartis AG
NYSE:NVS
$292.83B
Amgen Inc.
NASDAQ:AMGN
$191.12B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.61B
Pfizer Inc.
NYSE:PFE
$149.30B
Bristol-Myers Squibb Company
NYSE:BMY
$116.72B
GSK plc
NYSE:GSK
$106.61B
Sanofi
NASDAQ:SNY
$106.50B
SEC Filings
Recent regulatory filings
No filings found.
Does AZN generate free cash flow?
AstraZeneca PLC (AZN) generated $11.77B of free cash flow in fiscal 2025.
How much operating cash flow does AZN produce?
Operating cash flow was $14.57B, before capital expenditures of $2.81B.
Explore More
Continue the stock analysis
Jump to another research area for this company.